Clinician Interaction With a Prescription Digital Therapeutic for OUD: Engagement and Outcomes

Abstract: Background: Prescription digital therapeutics (PDTs) are U.S. Food and Drug Administration-authorized software-based treatments delivered on mobile devices. The reSET-O PDT for patients with opioid use disorder (OUD) is linked to a clinician-facing dashboard (Pear.MD). Objective: To assess clinician interactions with the dashboard and the association of such activity with patient engagement, retention, and abstinence. Methods: De-identified data were analyzed from patients who filled a reSET-O 12-week prescription. Provider interaction with the dashboard was defined as opening the dashboard at least once. Descriptive statistics assessed patterns of clinician interactions and patient outcomes. Results: Among 10,066 patients who filled prescriptions, 63.0% were managed via the dashboard. Patient engagement was numerically higher for managed vs. nonmanaged patients, including median days active in the PDT (23 vs. 19; Cohen’s d = 0.28) and median unique lessons completed (27 vs. 22; Cohen’s d = 0.21). Patient engagement was positively associated with increasing frequency of provider dashboard management. Increased odds of retention in weeks 9-12 of treatment were observed relative to nonmanagement by 1.1, 1.2, 2.0, and 2.8-fold for minimal; monthly; intensive; and weekly management, respectively. The percent of patients abstinent (missing weeks excluded) were 66.7% (h=0.04), 69.4%(h=0.10), 73.0%(h=0.18) and 73.8%(h=0.20) for minimal; monthly; intensive; and weekly management, respectively. Conclusions: Use and frequency of interaction with a clinician-facing dashboard are positively associated with higher levels of patient engagement, treatment retention, and abstinence in the last month of treatment. Interaction with the clinician-facing dashboard may improve outcomes and efficiency of care in patients with OUD.Short Description: This study assessed a clinician-facing dashboard for a prescription digital therapeutic (PDT) for patients with opioid use disorder (OUD). Clinician use and frequency of interaction with the dashboard were positively associated with higher levels of patient engagement, treatment retention, and abstinence in the last 4 weeks of the 12-week PDT prescription. Interaction with the clinician-facing dashboard may thus improve outcomes and efficiency of care in patients with OUD.Name of Sponsoring Organization(s): Pear Therapeutics (US), Inc.